Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (186)	2/11/2004 11:19:50 AM
From: Icebrg	Read Replies (2) of 946

>>When you say orphan drug status gives them a couple fo extra years in Europe . . . What year does it expire? Have they said anything about extending the patent in Europe?>> Tuck They got a 10 year exclusivity in 2000. So, that should protect them for another 6 years or so. I don't know anything about the European patent situation. Normally it is considered more difficult to be granted a patent over here. I don't think it matters too much to them. What they can do now and what I believe is their master plan is to create a European sales force in preparation for the launch of Xyotax and Pixantrone. With the help of Trisenox they are able to do so and more or less have this sales force paying its own costs. I believe they said that the plan is also to try to find some other niche products which they can distribute with the help of their European reps. Anyhow, it was a good move, but I don't think it will be significant for the bottom line. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next